Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.

Original languageEnglish (US)
Pages (from-to)e510-e514
JournalThe Lancet Oncology
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Quality of Life
Clinical Trials
Neoplasms
Product Labeling
Patient-Centered Care
Foster Home Care
Policy Making
Health Policy
Research
Publications
Decision Making
Patient Reported Outcome Measures
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. The Lancet Oncology, 17(11), e510-e514. https://doi.org/10.1016/S1470-2045(16)30510-1

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials : a start in setting international standards. / Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium.

In: The Lancet Oncology, Vol. 17, No. 11, 01.11.2016, p. e510-e514.

Research output: Contribution to journalReview article

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium 2016, 'Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards', The Lancet Oncology, vol. 17, no. 11, pp. e510-e514. https://doi.org/10.1016/S1470-2045(16)30510-1
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. The Lancet Oncology. 2016 Nov 1;17(11):e510-e514. https://doi.org/10.1016/S1470-2045(16)30510-1
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. / Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials : a start in setting international standards. In: The Lancet Oncology. 2016 ; Vol. 17, No. 11. pp. e510-e514.
@article{d38bfc85b3aa4d36a57020922ac079b9,
title = "Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards",
abstract = "Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.",
author = "{Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium} and Andrew Bottomley and Madeline Pe and Sloan, {Jeff A} and Ethan Basch and Franck Bonnetain and Melanie Calvert and Alicyn Campbell and Charles Cleeland and Kim Cocks and Laurence Collette and Amylou Dueck and Nancy Devlin and Flechtner, {Hans Henning} and Carolyn Gotay and Eva Greimel and Ingolf Griebsch and Mogens Groenvold and Hamel, {Jean Francois} and Madeleine King and Kluetz, {Paul G.} and Michael Koller and Malone, {Daniel C.} and Francesca Martinelli and Mitchell, {Sandra A.} and Moinpour, {Carol M.} and Jammbe Musoro and Daniel O'Connor and Kathy Oliver and Elisabeth Piault-Louis and Martine Piccart and Pimentel, {Francisco L.} and Chantal Quinten and Reijneveld, {Jaap C.} and Christoph Sch{\"u}rmann and Smith, {Ashley Wilder} and Soltys, {Katherine M.} and Taphoorn, {Martin J B} and Galina Velikova and Corneel Coens",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/S1470-2045(16)30510-1",
language = "English (US)",
volume = "17",
pages = "e510--e514",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials

T2 - a start in setting international standards

AU - Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium

AU - Bottomley, Andrew

AU - Pe, Madeline

AU - Sloan, Jeff A

AU - Basch, Ethan

AU - Bonnetain, Franck

AU - Calvert, Melanie

AU - Campbell, Alicyn

AU - Cleeland, Charles

AU - Cocks, Kim

AU - Collette, Laurence

AU - Dueck, Amylou

AU - Devlin, Nancy

AU - Flechtner, Hans Henning

AU - Gotay, Carolyn

AU - Greimel, Eva

AU - Griebsch, Ingolf

AU - Groenvold, Mogens

AU - Hamel, Jean Francois

AU - King, Madeleine

AU - Kluetz, Paul G.

AU - Koller, Michael

AU - Malone, Daniel C.

AU - Martinelli, Francesca

AU - Mitchell, Sandra A.

AU - Moinpour, Carol M.

AU - Musoro, Jammbe

AU - O'Connor, Daniel

AU - Oliver, Kathy

AU - Piault-Louis, Elisabeth

AU - Piccart, Martine

AU - Pimentel, Francisco L.

AU - Quinten, Chantal

AU - Reijneveld, Jaap C.

AU - Schürmann, Christoph

AU - Smith, Ashley Wilder

AU - Soltys, Katherine M.

AU - Taphoorn, Martin J B

AU - Velikova, Galina

AU - Coens, Corneel

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.

AB - Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.

UR - http://www.scopus.com/inward/record.url?scp=84995577351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995577351&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30510-1

DO - 10.1016/S1470-2045(16)30510-1

M3 - Review article

C2 - 27769798

AN - SCOPUS:84995577351

VL - 17

SP - e510-e514

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -